Triple
T2371140
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Perjeta |
E46091
|
entity |
| Predicate | clinicalTrial |
P23163
|
FINISHED |
| Object |
CLEOPATRA trial
The CLEOPATRA trial was a pivotal phase III clinical study that demonstrated improved survival by adding pertuzumab (Perjeta) to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
|
E261834
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69a88a145268819083e2736cb835c696 |
elicitation | completed |
| NER | batch_69abc771302481908540e31abb5aeeba |
ner | completed |
| NED1 | batch_69aea8a2b1448190b19179cf379993ee |
ned_source_triple | completed |
| NED2 | batch_69aead16b0a881909103e26053cfad84 |
ned_description | completed |
| NEDg | batch_69aeac6b13ac81909042dddef15ec924 |
nedg | completed |
Created at: March 4, 2026, 7:56 p.m.